Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Yoshiaki Goi"'
Autor:
Naoki, Aizawa, Yoshikazu, Fujimori, Osamu, Nakanishi, Takemitsu, Hayashi, Yoshiaki, Goi, Jun-Ichi, Kobayashi, Tomoe, Fujita
Publikováno v:
European journal of pharmacology. 899
Transient receptor potential melastatin 8 (TRPM8) channels may contribute to the pathophysiological bladder afferent hyperactivity, thus a TRPM8 antagonist would be a promising therapeutic target for the bladder hypersensitive disorders including uri
Autor:
Takemitsu Hayashi, Jun-ichi Kobayashi, Tomoe Fujita, Yoshiaki Goi, Naoki Aizawa, Osamu Nakanishi, Yoshikazu Fujimori
Publikováno v:
European Journal of Pharmacology. 899:173995
Transient receptor potential melastatin 8 (TRPM8) channels may contribute to the pathophysiological bladder afferent hyperactivity, thus a TRPM8 antagonist would be a promising therapeutic target for the bladder hypersensitive disorders including uri
Autor:
Kazuyasu Maruyama, Itaru Maruyama, Yoshitaka Tomiyama, Osamu Yamaguchi, Mamoru Kobayashi, Yoshiaki Goi, Masanori Nomiya, Satoshi Tatemichi
Publikováno v:
Pharmacology. 97:161-170
Background/Aims: This study was performed to investigate the detailed mechanism underlying the effects of the selective α1A-adrenoceptor antagonist, silodosin, on bladder function in a rat model of atherosclerosis-induced chronic bladder ischemia (C
Autor:
Yoshitaka Tomiyama, Kazuyasu Maruyama, Ayaka Yokoyama, Mamoru Kobayashi, Osamu Yamaguchi, Satoshi Tatemichi, Yoshiaki Goi
Publikováno v:
European Journal of Pharmacology. 764:489-496
This study was performed to investigate the effects of silodosin (selective α1A-adrenoceptor antagonist) on bladder blood flow (BBF) and bladder function in a rat model of bladder outlet obstruction (BOO) and to determine the expression of α1-adren
Publikováno v:
Journal of Urology. 190:1116-1122
We investigated the effects of the selective α1A-adrenoceptor antagonist silodosin on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction.The chronic bladder i
Autor:
Yoshinobu Yamazaki, Yuji Hoyano, Itaru Maruyama, Kazuyasu Maruyama, Satoshi Tatemichi, Yoshiaki Goi, Hiroshi Kusama
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 385:845-852
We performed in vitro and in vivo experiments to evaluate the pharmacological profile of ritobegron and its effects on the bladder in rats. β3-AR selectivity was assessed using CHO cells expressing various subtypes of the human β-adrenoceptor (AR).
Autor:
Kyosuke Ueda, Rina Tanaka, Yoshiaki Goi, Kenji Ishihara, Hiroshi Ohtsu, Takayuki Narushima, Kazuo Ohuchi, Noriyasu Hirasawa, Masahiro Hiratsuka
Publikováno v:
Inflammation and Regeneration. 31:302-306
Biodevices are implanted for long periods of time, so the release of metal ions from alloys should be tested in tissues to assess the risk of inducing metal allergies. However there is little evidence that the release of metal ions from alloys in viv
Autor:
Noriyasu Hirasawa, Kenji Ishihara, Jang Ja Hong, Hiroshi Ohtsu, Kazuo Ohuchi, Hiroshi Wada, Yoshiaki Goi, Toshio Seyama
Publikováno v:
International Archives of Allergy and Immunology. 149:57-60
Background: Accessories, watches, coins and other items containing metal sometimes cause contact dermatitis and metal allergy. Among metals, nickel in alloys is ionized by sweat on the surface of the skin and exhibits particularly marked irritancy an
Autor:
Yoshiaki, Goi, Yoshitaka, Tomiyama, Itaru, Maruyama, Satoshi, Tatemichi, Kazuyasu, Maruyama, Mamoru, Kobayashi, Masanori, Nomiya, Osamu, Yamaguchi
Publikováno v:
Pharmacology. 97(3-4)
This study was performed to investigate the detailed mechanism underlying the effects of the selective α(1A)-adrenoceptor antagonist, silodosin, on bladder function in a rat model of atherosclerosis-induced chronic bladder ischemia (CBI).The CBI mod
Autor:
Itaru Maruyama, Satoshi Tatemichi, Yuji Hoyano, Yoshiaki Goi, Yoshinobu Yamazaki, Hiroshi Kusama, Kazuyasu Maruyama
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 342(1)
We evaluated the pharmacological profile of ritobegron [KUC-7483; (−)-ethyl 2-[4-(2-{[(1 S ,2 R )-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)-2,5-dimethylphenyloxy]acetate monohydrochloride] and its effects on the bladder in cynomolgus